Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18228
Abstract: cell neoplasms. Bortezomib, a proteasome inhibitor initially used in multiple myeloma, has been combined with chemotherapy and shown to be effective in frontline PBL. 5 In the relapsed setting, PBL treatment is even more difficult… read more here.
Keywords: daratumumab; ifosfamide carboplatin; daratumumab ifosfamide; four patients ... See more keywords